AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...
Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...
A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients ...
UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...
Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, a research team led by Christian ...
Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells ...
Looking to build a new laboratory or expand your existing facility. Talk to your Formaspace Design Consultant about our custom lab furniture solutions, built in the USA, at our Austin, Texas, factory ...
Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results